These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15808387)

  • 21. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
    Cady R; Schreiber C
    Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Persistence with overactive bladder pharmacotherapy in a Medicaid population.
    Shaya FT; Blume S; Gu A; Zyczynski T; Jumadilova Z
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S121-9. PubMed ID: 16161385
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder.
    Preik M; Albrecht D; O'Connell M; Hampel C; Anderson R
    BJU Int; 2004 Oct; 94(6):821-7. PubMed ID: 15476516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study.
    Staskin DR; Dmochowski RR; Sand PK; Macdiarmid SA; Caramelli KE; Thomas H; Hoel G
    J Urol; 2009 Apr; 181(4):1764-72. PubMed ID: 19233423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Economic impact of extended-release tolterodine versus immediate- and extended-release oxybutynin among commercially insured persons with overactive bladder.
    Varadharajan S; Jumadilova Z; Girase P; Ollendorf DA
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S140-9. PubMed ID: 16161387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study.
    Sand P; Zinner N; Newman D; Lucente V; Dmochowski R; Kelleher C; Dahl NV
    BJU Int; 2007 Apr; 99(4):836-44. PubMed ID: 17187655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial.
    Chu FM; Dmochowski RR; Lama DJ; Anderson RU; Sand PK
    Am J Obstet Gynecol; 2005 Jun; 192(6):1849-54; discussion 1854-5. PubMed ID: 15970828
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of transdermal and oral oxybutynin in children with neurogenic detrusor overactivity.
    Cartwright PC; Coplen DE; Kogan BA; Volinn W; Finan E; Hoel G
    J Urol; 2009 Oct; 182(4):1548-54. PubMed ID: 19683731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Management of hyposalivation caused by oxybutynin chloride in the treatment of the unstable bladder].
    Arango Toro O; Nohales Taurines G; Cortadellas Angel R; Castro Santamaría R; Gelabert Mas A
    Actas Urol Esp; 1998 Feb; 22(2):124-30. PubMed ID: 9586268
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial.
    Wang AC; Chih SY; Chen MC
    Urology; 2006 Nov; 68(5):999-1004. PubMed ID: 17113893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oxybutynin for refractory hot flashes in cancer patients.
    Sexton T; Younus J; Perera F; Kligman L; Lock M
    Menopause; 2007; 14(3 Pt 1):505-9. PubMed ID: 17204995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Therapeutic value of moderate-dose oxybutynin in extensive hyperhidrosis].
    Maillard H; Fenot M; Bara C; Célérier P
    Ann Dermatol Venereol; 2011 Oct; 138(10):652-6. PubMed ID: 21978500
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics.
    Schmid DM; Sauermann P; Werner M; Schuessler B; Blick N; Muentener M; Strebel RT; Perucchini D; Scheiner D; Schaer G; John H; Reitz A; Hauri D; Schurch B
    J Urol; 2006 Jul; 176(1):177-85. PubMed ID: 16753396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Medical costs after initiation of drug treatment for overactive bladder: effects of selection bias on cost estimates.
    Nitz NM; Jumadilova Z; Darkow T; Frytak JR; Bavendam T
    Am J Manag Care; 2005 Jul; 11(4 Suppl):S130-9. PubMed ID: 16161386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improved efficacy of extended release oxybutynin in children with persistent daytime urinary incontinence converted from regular oxybutynin.
    Van Arendonk KJ; Knudson MJ; Austin JC; Cooper CS
    Urology; 2006 Oct; 68(4):862-5. PubMed ID: 17070368
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Intravesical drug therapy in women with severe urge incontinence. Clinical experiences from a department of gynecology].
    Johansen JK; Lose G
    Ugeskr Laeger; 1999 Nov; 161(44):6052-5. PubMed ID: 10778341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of tension-free vaginal tape on overactive bladder symptoms in women with stress urinary incontinence: significance of detrusor overactivity.
    Choe JH; Choo MS; Lee KS
    J Urol; 2008 Jan; 179(1):214-9. PubMed ID: 18001792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-dose oxybutynin for the treatment of urge incontinence: good efficacy and few side effects.
    Bemelmans BL; Kiemeney LA; Debruyne FM
    Eur Urol; 2000 Jun; 37(6):709-13. PubMed ID: 10828672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study.
    Grosse J; Kramer G; Jakse G
    BJU Int; 2009 Sep; 104(5):651-6. PubMed ID: 19281462
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.